Tarextumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | Notch 2, Notch 3 |
| Clinical data | |
| Other names | OMP-59R5 |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6338H9804N1700O1990S48 |
| Molar mass | 143196.94 g·mol−1 |
Tarextumab (formerly OMP-59R5) is a fully human monoclonal antibody targeting the Notch 2/3 receptors. It is being tested as a possible treatment for cancer. In January 2015, the US FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and lung cancer. Two early stage clinical trials have reported encouraging results.